Gradient Investments’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Gradient Investments’s Portfolio OPNT Stock Details OPNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-350	Closed	-$5K	–	1041
2018 Q4	$5K	Hold	350	–	–	﹤0.01%	721
2018 Q3	$6K	Hold	350	–	–	﹤0.01%	722
2018 Q2	$5K	Buy	+350	New	+$6.16K	﹤0.01%	735

Other funds holding OPNT

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Gradient Investments's OPNT Position: Q1 2019 in Review

Gradient Investments sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2019, closing a stake of 350 shares — an estimated $5K sold.

Gradient Investments first reported a position in OPNT in Q2 2018 and held it in 3 quarters. The position peaked at $6K in Q3 2018. 23 funds tracked by Wall St. Rank hold OPNT as of Q1 2019.

Gradient Investments reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Gradient Investments sold 350 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2019, an estimated $5K.
Gradient Investments first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 3 quarters.
Gradient Investments's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $6K in Q3 2018.
23 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2019.

Based on Gradient Investments's 13F filing for Q1 2019, filed 11 Apr 2019.